Drug lookup
Drug reference

Dinoprostone

Vasodilator · Labour induction, Cervical ripening

Also known as PROPESS, PROSTIN E2 VAGINAL GEL, PROSTIN E2 VAGINAL TABLETS

VasodilatorLabour induction, Cervical ripening
CDSCO approved
EXCRETION
not curated
INTERACTIONS
5 major
SEVERE in our sources
PREGNANCY
not curated
Top interactionssee all 6
  • ErgometrineSevereDatabaseDDInter
  • MethylergometrineSevereDatabaseDDInter
  • MifepristoneSevereDatabaseDDInter
  • OxytocinSevereDatabaseDDInter

Mechanism

Prostaglandins induce uterine contractions. Dinoprostone is used to induce abortion or induce or augment labour and to minimise blood loss from the placental site.

Indications

Cervical ripening and induction of labour at term (PROPESS®)Induction of labour (PROSTIN E2® VAGINAL GEL)Induction of labour (unfavourable primigravida) (PROSTIN E2® VAGINAL GEL)Induction of labour (PROSTIN E2® VAGINAL TABLETS)facilitation of labor (cervical ripening)treatment of postpartum hemorrhageInduction/augmentation of labourMidterm abortionCervical priming (ripening)

Dosing

Adult
PROPESS® (Cervical ripening and induction of labour at term): 1 pessary, insert high into posterior fornix and remove when cervical ripening adequate; if oxytocin necessary, remove 30 minutes before oxytocin infusion; remove if cervical ripening inadequate after 24 hours (dose not to be repeated).…
Renal adjustment
Manufacturers advise avoid.
Hepatic adjustment
Manufacturer advises avoid.
Max dose
PROSTIN E2® VAGINAL GEL (Induction of labour): Maximum 3 mg per course. PROSTIN E2® VAGINAL GEL (Induction of labour, unfavourable primigravida): Maximum 4 mg per course. PROSTIN E2® VAGINAL TABLETS (Induction of labour): Maximum 6 mg per course. PROPESS®: Dose not to be repeated after 24 hours.

Pharmacokinetics

Bioavailability
Prostin E2 Vaginal tablets and Vaginal Gel are not bioequivalent.

Contraindications

  • Active cardiac disease
  • Active pulmonary disease
  • Avoid extra-amniotic route in cervicitis or vaginitis
  • Fetal distress
  • Fetal malpresentation
  • Grand multiparas
  • History of caesarean section
  • History of difficult or traumatic delivery
  • History of major uterine surgery
  • Major cephalopelvic disproportion
  • Multiple pregnancies
  • history of asthma
  • glaucoma
  • myocardial infarction

Side effects

Common
Amniotic cavity infectionFebrile disordersHeadacheHyperbilirubinaemia neonatalHypotensionPruritusUterine atonyVaginal burningAbdominal painDiarrhoeaGenital oedemaNauseaVomitingWatery diarrhoeaUterine crampsUnduly forceful uterine contractionsVaginal bleedingFlushingShiveringFeverMalaiseFall in BPTachycardiaChest pain
Serious
  • Disseminated intravascular coagulation
  • Uterine rupture
  • uterine hyperstimulation

Drug interactions

Ergometrine
Severe
Database

Clinical effect not specified

Source: DDInter

Methylergometrine
Severe
Database

Clinical effect not specified

Source: DDInter

Mifepristone
Severe
Database

Clinical effect not specified

Source: DDInter

Oxytocin
Severe
Database

Clinical effect not specified

Source: DDInter

Urea
Severe
Database

Clinical effect not specified

Source: DDInter

Misoprostol
Moderate
Database

Additive uterotonic effects; increased risk of uterine tachysystole.

Avoid sequential use without washout period; monitor closely.

Source: Kimi deep-research + Cla

Related guidelines

Other Vasodilator drugs

Ask House about Dinoprostone

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-13 · House clinical team